MedTrace Logo

Safety, Reactogenicity, and Immunogenicity of mRNA-1653 in Healthy Adults

NCT03392389 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 124

Last updated 2020-02-06

No results posted yet for this study

Summary

This clinical study will assess the safety, reactogenicity and immunogenicity of mRNA-1653, a combined human metapneumovirus and human parainfluenza virus type 3 vaccine in healthy adults.

Conditions

  • Human Metapneumovirus and Human Parainfluenza Infection

Interventions

BIOLOGICAL

mRNA-1653

Escalating dose levels

OTHER

Placebo

Saline

Sponsors & Collaborators

  • ModernaTX, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
49 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-12-04
Primary Completion
2019-07-29
Completion
2019-07-29
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03392389 on ClinicalTrials.gov